drugset / Trial / NCT07100067
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
Recruiting
35 enrolled
Nanjing Legend Biotech Co.
Institute of Hematology & Blood Diseases Hospital, China · collab
NaSingle-groupOpen-labelTreatment
Summary
A prospective, single-arm, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-F33S in patients with relapsed/refractory multiple myeloma(Investigator-initiated Study).
Timeline
- Start
- 2025-09-16
- Primary completion
- 2028-02-20
- Completion
- 2029-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LCAR-F33S | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |